Skip to main content
Premium Trial:

Request an Annual Quote

PathGroup, CCE Partner to Provide PGx Capabilities to Community-based Oncologists

NEW YORK (GenomeWeb) – PathGroup and Cancer Clinics of Excellence today announced a partnership aimed at improving the ability of community-based oncologists to make personalized therapeutic decisions.

CCE has chosen PathGroup as a preferred laboratory service provider, and oncologists in CCE's network will now have access to tests and data generated by PathGroup using its SmartGenomics platform, which generates information about patient drug targets so physicians can make more precise, personalized therapeutic recommendations.

SmartGenomics uses several different technologies, including next-generation sequencing, array comparative genomic hybridization, immunohistochemistry, and fluorescent in situ hybridization, to profile a patient's cancer. The platform is supported by a bioinformatics pipeline from GenoSpace and Thomson Reuters, and provides oncologists with prognostic, predictive, and therapeutic information, and links the findings with clinical trial options, according to PathGroup.

Pranil Chandra, director of molecular pathology services at PathGroup, said in a statement that 80 percent of cancer patients are currently seen by community-based oncologists, and SmartGenomics provides them with access to academic-level medicine and cutting-edge therapies.